MA53927A - Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel - Google Patents

Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel

Info

Publication number: MA53927A
Authority: MA; Morocco
Prior art keywords: salt; pharmaceutical composition; oral administration; aminopyrimidine derivative; aminopyrimidine
Prior art date: 2018-10-18

Application number

MA053927A

Other languages

English (en)

Other versions

MA53927B1 (fr

Inventor

Seongkyu Kim

Soo-Won Kim

Deokkyu Lee

Yoong-Sik Park

Jun-Mo Yang

Original Assignee

Yuhan Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-10-18

Filing date

2019-10-17

Publication date

2021-09-15

2019-10-17 Application filed by Yuhan Corp filed Critical Yuhan Corp

2021-09-15 Publication of MA53927A publication Critical patent/MA53927A/fr

2023-12-29 Publication of MA53927B1 publication Critical patent/MA53927B1/fr

Links

150000005005 aminopyrimidines Chemical class 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Immunology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Psychology (AREA)

MA53927A 2018-10-18 2019-10-17 Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel MA53927B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
KR1020180124171A KR20200043618A (ko)	2018-10-18	2018-10-18	아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
PCT/IB2019/058862 WO2020079637A1 (fr)	2018-10-18	2019-10-17	Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel

Publications (2)

Publication Number	Publication Date
MA53927A true MA53927A (fr)	2021-09-15
MA53927B1 MA53927B1 (fr)	2023-12-29

Family

ID=70282933

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA53927A MA53927B1 (fr)	2018-10-18	2019-10-17	Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel

Country Status (31)

Country	Link
US (1)	US12318390B2 (fr)
EP (2)	EP3866767B1 (fr)
JP (2)	JP7369769B2 (fr)
KR (3)	KR20200043618A (fr)
CN (2)	CN119523922A (fr)
AR (1)	AR117655A1 (fr)
AU (2)	AU2019360446B2 (fr)
BR (1)	BR112021007061A2 (fr)
CA (1)	CA3116652A1 (fr)
DK (1)	DK3866767T3 (fr)
EA (1)	EA202191061A1 (fr)
ES (1)	ES2968966T3 (fr)
FI (1)	FI3866767T3 (fr)
HR (1)	HRP20231670T1 (fr)
HU (1)	HUE065389T2 (fr)
IL (1)	IL282163B2 (fr)
LT (1)	LT3866767T (fr)
MA (1)	MA53927B1 (fr)
MD (1)	MD3866767T2 (fr)
MX (2)	MX2021004457A (fr)
MY (1)	MY208983A (fr)
PE (1)	PE20211818A1 (fr)
PH (1)	PH12021550687A1 (fr)
PL (1)	PL3866767T3 (fr)
PT (1)	PT3866767T (fr)
RS (1)	RS65012B1 (fr)
SG (1)	SG11202103057RA (fr)
SI (1)	SI3866767T1 (fr)
SM (1)	SMT202300491T1 (fr)
TW (1)	TWI831848B (fr)
WO (1)	WO2020079637A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR111469A1 (es)	2017-04-21	2019-07-17	Yuhan Corp	Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
US11850248B2 (en)	2019-05-14	2023-12-26	Yuhan Corporation	Therapies with 3rd generation EGFR tyrosine kinase inhibitors
US11879013B2 (en) *	2019-05-14	2024-01-23	Janssen Biotech, Inc.	Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
JP7783182B2 (ja)	2020-02-12	2025-12-09	ヤンセンバイオテツク，インコーポレーテツド	ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療
US12138351B2 (en)	2020-04-14	2024-11-12	Janssen Biotech, Inc.	Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof
WO2022253261A1 (fr)	2021-06-01	2022-12-08	杭州领业医药科技有限公司	Forme cristalline d'hydrate de méthanesulfonate de lazertinib, son procédé de préparation et son utilisation
CA3228195A1 (en)	2023-05-23	2025-06-30	Janssen Biotech, Inc.	Methods for treatment of non-small cell lung cancer (nsclc)
AU2024337472A1 (en)	2023-09-05	2026-04-16	Janssen Biotech, Inc.	Methods of treating non-small cell lung cancer
WO2025206726A1 (fr) *	2024-03-26	2025-10-02	(주)신테카바이오	Composition pharmaceutique pour la prévention ou le traitement de maladies liées à la dépression ou à l'anxiété, contenant du lazertinib ou un sel pharmaceutiquement acceptable de celui-ci
WO2026042017A1 (fr)	2024-08-19	2026-02-26	Janssen Biotech, Inc.	Amivantamab en association avec le lazertinib pour le traitement du cancer du poumon non à petites cellules (cpnpc)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ509378A (en)	1998-07-20	2003-04-29	Smithkline Beecham Corp	Amorphous ammonium salts of eprosartan and pharmaceuticals thereof, useful for blocking angiotensin II receptors and useful for treating hypertension, congestive heart disease and renal failure
DE10319450A1 (de)	2003-04-30	2004-11-18	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pharmazeutische Formulierung des Telmisartan Natriumsalzes
ES2359377T3 (es) *	2006-10-27	2011-05-23	Fmc Corporation	Celulosa microcristalina coprocesada y alcohol de azúcar como excipiente para formulaciones de comprimidos.
US7998505B2 (en)	2006-10-27	2011-08-16	Fmc Corporation	Dry granulation binders, products, and use thereof
WO2013016694A2 (fr) *	2011-07-27	2013-01-31	Cornell University	Procédé pour la détection et la quantification d'arn
RU2627471C2 (ru)	2011-09-14	2017-08-08	Селджин Корпорейшн	Препараты { 2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил} амида циклопропанкарбоновой кислоты
JP5899327B2 (ja)	2011-11-29	2016-04-06	ギリアドファーマセットエルエルシー	Ｃ型肝炎ウイルスを処置するための組成物および方法
WO2014175986A2 (fr) *	2013-04-23	2014-10-30	RevOrtho LLC	Procédé et système de reconstruction de hanche modulaire
GB201400034D0 (en)	2014-01-02	2014-02-19	Astrazeneca Ab	Pharmaceutical Compositions comprising AZD9291
HUE054848T2 (hu)	2014-10-13	2021-09-28	Yuhan Corp	Vegyületek és készítmények EGFR mutáns kináz aktivitás módosítására
CN107108524A (zh)	2014-12-16	2017-08-29	西格诺药品有限公司	2‑(叔丁基氨基)‑4‑((1r,3r,4r)‑3‑羟基‑4‑甲基环己基氨基)‑嘧啶‑5‑甲酰胺的配制物
CN104788427B (zh) *	2015-02-05	2017-05-31	上海泓博智源医药股份有限公司	3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
MX2017014987A (es)	2015-05-22	2018-04-13	Novartis Ag	Composiciones farmaceuticas.
KR102488488B1 (ko)	2015-10-07	2023-01-12	쿄와 기린 가부시키가이샤	아릴알킬아민 화합물 함유 의약 조성물
SG11201808626WA (en)	2016-04-07	2018-10-30	Chemocentryx Inc	Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
AR111469A1 (es) *	2017-04-21	2019-07-17	Yuhan Corp	Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
US12138351B2 (en) *	2020-04-14	2024-11-12	Janssen Biotech, Inc.	Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof

2018
- 2018-10-18 KR KR1020180124171A patent/KR20200043618A/ko active Pending
2019
- 2019-10-17 MY MYPI2021002062A patent/MY208983A/en unknown
- 2019-10-17 KR KR1020257002203A patent/KR20250025475A/ko active Pending
- 2019-10-17 MX MX2021004457A patent/MX2021004457A/es unknown
- 2019-10-17 CA CA3116652A patent/CA3116652A1/fr active Pending
- 2019-10-17 SM SM20230491T patent/SMT202300491T1/it unknown
- 2019-10-17 WO PCT/IB2019/058862 patent/WO2020079637A1/fr not_active Ceased
- 2019-10-17 PL PL19872427.0T patent/PL3866767T3/pl unknown
- 2019-10-17 RS RS20231252A patent/RS65012B1/sr unknown
- 2019-10-17 TW TW108137395A patent/TWI831848B/zh active
- 2019-10-17 HU HUE19872427A patent/HUE065389T2/hu unknown
- 2019-10-17 BR BR112021007061-3A patent/BR112021007061A2/pt unknown
- 2019-10-17 EP EP19872427.0A patent/EP3866767B1/fr active Active
- 2019-10-17 CN CN202411659054.9A patent/CN119523922A/zh active Pending
- 2019-10-17 SI SI201930673T patent/SI3866767T1/sl unknown
- 2019-10-17 PE PE2021000495A patent/PE20211818A1/es unknown
- 2019-10-17 KR KR1020217014600A patent/KR102760314B1/ko active Active
- 2019-10-17 JP JP2021520564A patent/JP7369769B2/ja active Active
- 2019-10-17 CN CN201980068641.1A patent/CN113015521B/zh active Active
- 2019-10-17 EP EP23211951.1A patent/EP4306113A3/fr active Pending
- 2019-10-17 DK DK19872427.0T patent/DK3866767T3/da active
- 2019-10-17 MD MDE20210799T patent/MD3866767T2/ro unknown
- 2019-10-17 LT LTEPPCT/IB2019/058862T patent/LT3866767T/lt unknown
- 2019-10-17 EA EA202191061A patent/EA202191061A1/ru unknown
- 2019-10-17 MA MA53927A patent/MA53927B1/fr unknown
- 2019-10-17 FI FIEP19872427.0T patent/FI3866767T3/fi active
- 2019-10-17 AU AU2019360446A patent/AU2019360446B2/en active Active
- 2019-10-17 PT PT198724270T patent/PT3866767T/pt unknown
- 2019-10-17 HR HRP20231670TT patent/HRP20231670T1/hr unknown
- 2019-10-17 US US17/285,161 patent/US12318390B2/en active Active
- 2019-10-17 ES ES19872427T patent/ES2968966T3/es active Active
- 2019-10-17 SG SG11202103057RA patent/SG11202103057RA/en unknown
- 2019-10-17 IL IL282163A patent/IL282163B2/en unknown
- 2019-10-18 AR ARP190102972A patent/AR117655A1/es unknown
2021
- 2021-03-25 PH PH12021550687A patent/PH12021550687A1/en unknown
- 2021-04-16 MX MX2023014946A patent/MX2023014946A/es unknown
2023
- 2023-10-16 JP JP2023177976A patent/JP2024016052A/ja not_active Withdrawn
2024
- 2024-09-02 AU AU2024216519A patent/AU2024216519B2/en active Active

Also Published As

Publication number	Publication date
RS65012B1 (sr)	2024-01-31
PE20211818A1 (es)	2021-09-14
JP2024016052A (ja)	2024-02-06
FI3866767T3 (fi)	2024-01-30
EP4306113A3 (fr)	2024-02-14
MY208983A (en)	2025-06-14
MX2021004457A (es)	2021-07-07
EP3866767B1 (fr)	2023-11-29
KR20210061457A (ko)	2021-05-27
IL282163B1 (en)	2025-05-01
US12318390B2 (en)	2025-06-03
PH12021550687A1 (en)	2022-02-14
BR112021007061A2 (pt)	2021-07-20
CA3116652A1 (fr)	2020-04-23
AU2019360446A1 (en)	2021-04-22
AU2024216519B2 (en)	2025-11-20
JP7369769B2 (ja)	2023-10-26
HRP20231670T1 (hr)	2024-03-15
WO2020079637A9 (fr)	2020-07-23
JP2022504943A (ja)	2022-01-13
TWI831848B (zh)	2024-02-11
KR102760314B1 (ko)	2025-02-03
MD3866767T2 (ro)	2024-06-30
WO2020079637A1 (fr)	2020-04-23
EP4306113A2 (fr)	2024-01-17
EP3866767A4 (fr)	2022-07-20
CN113015521A (zh)	2021-06-22
AU2024216519A1 (en)	2024-09-19
SMT202300491T1 (it)	2024-01-10
NZ774402A (en)	2024-08-30
AU2019360446B2 (en)	2024-09-19
CN119523922A (zh)	2025-02-28
MA53927B1 (fr)	2023-12-29
HUE065389T2 (hu)	2024-05-28
IL282163A (en)	2021-05-31
PL3866767T3 (pl)	2024-04-02
EP3866767A1 (fr)	2021-08-25
KR20250025475A (ko)	2025-02-21
US20210322428A1 (en)	2021-10-21
TW202034903A (zh)	2020-10-01
DK3866767T3 (da)	2024-01-29
CN113015521B (zh)	2025-05-13
SI3866767T1 (sl)	2024-02-29
IL282163B2 (en)	2025-09-01
KR20200043618A (ko)	2020-04-28
ES2968966T3 (es)	2024-05-14
MX2023014946A (es)	2024-02-20
EA202191061A1 (ru)	2021-07-09
AR117655A1 (es)	2021-08-25
PT3866767T (pt)	2024-01-18
SG11202103057RA (en)	2021-05-28
LT3866767T (lt)	2023-12-27

Publication	Publication Date	Title
EP3866767A4 (fr)	2022-07-20	Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel
EP3941924A4 (fr)	2022-12-28	Technologies utiles pour la préparation d'oligonucléotides
EP4087406A4 (fr)	2024-01-10	Compositions vésiculaires pour une administration par voie orale
EP3875085A4 (fr)	2022-07-27	Suspension d'édaravone destinée à être administrée par voie orale
MA50557A (fr)	2020-09-16	Pistons pour dispositifs d'administration de médicament
EP3256149A4 (fr)	2019-08-14	Formulations pour administration orale d'agents actifs
EP3616696A4 (fr)	2021-01-27	Composition pharmaceutique contenant de l'enzalutamide pouvant être administrée par voie orale
MA49253A (fr)	2020-04-15	Compositions solides pour administration orale
MA56102A (fr)	2022-04-13	Formulations pharmaceutique d'inhibiteurs de fcrn appropriées pour une administration par voie sous-cutanée
EP3500291A4 (fr)	2020-03-11	Formulations pour l'administration par voie orale d'agents actifs
EP3498264A4 (fr)	2020-03-11	Préparation pharmaceutique pour administration orale à vitesse de dissolution contrôlée, la préparation comprenant des pastilles à libération prolongée contenant du chlorhydrate de tamsulosine
EP3313379A4 (fr)	2019-04-10	Forme posologique pharmaceutique par voie orale pour l'administration d'un peptide et/ou d'une protéine
MA52154A (fr)	2020-06-10	Composition pharmaceutique pour l'anémie
EP3471829A4 (fr)	2020-01-15	Système d'administration de médicaments pour l'administration d'agents antiviraux
EP3454868A4 (fr)	2019-12-18	Système d'administration de médicaments pour l'administration d'agents antiviraux
EP3318259A4 (fr)	2019-02-27	Composition pharmaceutique stable pour administration par voie orale
EP4046498A4 (fr)	2022-11-16	Composition pour inhiber la production de hmf comprenant de l'allulose disaccharide
EP4015001A4 (fr)	2023-06-14	Composition pharmaceutique orale
EP3801539A4 (fr)	2022-02-23	Compositoins pharmaceutiques solides d'administration par voie orale comprenant de la linagliptine
EP3829576A4 (fr)	2022-05-11	Composition pharmaceutique comprenant de l'eltrombopag olamine
EP3852731A4 (fr)	2022-06-15	Microsphères emboliques radio-opaques biorésorbables poreuses pour l'administration de médicaments
EP3326628A4 (fr)	2019-03-20	Composition pharmaceutique pour l'administration par voie orale comprenant un taxane à haute concentration
EP3609508A4 (fr)	2021-02-10	Système d'administration de médicament pour l'administration d'agents antiviraux
EP3843785A4 (fr)	2022-06-01	Compositions comprenant des stimulants de la perméation pour l'administration de médicaments
EP3845230A4 (fr)	2022-06-01	Composition pharmaceutique pour administration par voie orale